Medicare Enrolled
Dr. Evangeline Reyes, M.D.
Optician · Corona, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Reyes from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Reyes?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Reyes
Dr. Evangeline Reyes is an optician specialist in Corona, CA, with 20 years of NPI registration. Based on federal Medicare data, Dr. Reyes performed 30,643 Medicare services across 422 unique beneficiaries.
Between the years covered by Open Payments, Dr. Reyes received a total of $19,713 from 91 pharmaceutical and/or device companies across 1070 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in optician. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Reyes is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 3% volume in CA
$19,713 industry payments
Medicare Practice Summary
Medicare Utilization ↗30,643
Medicare services
Top 3% in CA for optician
422
Unique beneficiaries
$3
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~1,532 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Injectafer) An intravenous injection of ferric carboxymaltose, an iron replacement medication. |
19,500 | $1 | $8 |
| Iron infusion (Feraheme) An injection of ferumoxytol used to treat iron deficiency anemia in patients not on dialysis. |
10,200 | $0 | $5 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
284 | $99 | $250 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
107 | $108 | $290 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
95 | $24 | $75 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
83 | $11 | $75 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
71 | $53 | $150 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
65 | $145 | $300 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
55 | $59 | $125 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
52 | $8 | $15 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
41 | $8 | $25 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
40 | $94 | $225 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
26 | $135 | $330 |
| New patient office visit, complex (60-74 min) | 24 | $173 | $375 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
97.8% high complexity
0.3% medium
1.9% routine
Industry Payment Transparency
Open Payments through 2024 ↗$19,713
Total received (2018-2024)
Avg $2,816/year across 7 years
Top 9% in CA for optician
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
91
Companies
1,070
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$19,051 (96.6%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$662 (3.4%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$778
2023
$4,205
2022
$4,009
2021
$2,884
2020
$2,538
2019
$2,825
2018
$2,474
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Janssen Biotech, Inc.
$188
Takeda Pharmaceuticals U.S.A., Inc.
$103
Celgene Corporation
$71
Merck Sharp & Dohme LLC
$57
SpringWorks Therapeutics, Inc.
$56
Novartis Pharmaceuticals Corporation
$55
Astellas Pharma US Inc
$45
Rigel Pharmaceuticals, Inc.
$34
PharmaEssentia USA Corporation
$31
Myriad Genetic Laboratories, Inc.
$26
ABBVIE INC.
$20
EMD Serono, Inc.
$18
Exelixis Inc.
$18
GlaxoSmithKline, LLC.
$15
Spectrum Pharmaceuticals Inc.
$14
Lilly USA, LLC
$14
E.R. Squibb & Sons, L.L.C.
$13
Top 3 companies account for 46.6% of 2024 payments
All-time payments by company (2018-2024) ›
E.R. Squibb & Sons, L.L.C.
$1,661
Novartis Pharmaceuticals Corporation
$1,439
Merck Sharp & Dohme Corporation
$1,105
GENZYME CORPORATION
$1,009
PFIZER INC.
$858
AstraZeneca Pharmaceuticals LP
$812
GlaxoSmithKline, LLC.
$787
Janssen Biotech, Inc.
$775
Amgen Inc.
$770
Celgene Corporation
$702
Merck Sharp & Dohme LLC
$614
Incyte Corporation
$612
Genentech USA, Inc.
$466
Pharmacyclics LLC, An AbbVie Company
$398
Seagen Inc.
$393
NOVARTIS PHARMACEUTICALS CORPORATION
$378
Astellas Pharma US Inc
$359
Takeda Pharmaceuticals U.S.A., Inc.
$355
Gilead Sciences, Inc.
$331
Boehringer Ingelheim Pharmaceuticals, Inc.
$315
Rigel Pharmaceuticals, Inc.
$303
Lilly USA, LLC
$298
Dendreon Pharmaceuticals LLC
$233
AVEO Pharmaceuticals, Inc.
$213
Pharmacyclics LLC, an AbbVie Company
$189
BeiGene USA, Inc.
$184
Karyopharm Therapeutics Inc.
$158
TerSera Therapeutics LLC
$157
Teva Pharmaceuticals USA, Inc.
$152
Regeneron Healthcare Solutions, Inc.
$144
Puma Biotechnology, Inc.
$137
Bayer Healthcare Pharmaceuticals Inc.
$136
Dova Pharmaceuticals
$130
Blueprint Medicines Corporation
$123
PUMA BIOTECHNOLOGY, INC.
$118
Exelixis Inc.
$115
EMD Serono, Inc.
$112
EUSA Pharma (US) LLC
$111
Eisai Inc.
$110
CSL Behring
$110
Octapharma USA, Inc.
$108
Epizyme, Inc.,
$102
AbbVie Inc.
$102
SANOFI-AVENTIS U.S. LLC
$100
ABBVIE INC.
$99
ARRAY BIOPHARMA INC
$97
Kite Pharma, Inc.
$97
Ipsen Biopharmaceuticals, Inc
$88
Foundation Medicine, Inc.
$80
Daiichi Sankyo Inc.
$79
Immunocore Limited
$76
Otsuka America Pharmaceutical, Inc.
$69
Alexion Pharmaceuticals, Inc.
$64
SpringWorks Therapeutics, Inc.
$56
Taiho Oncology, Inc.
$56
INSYS Therapeutics Inc
$52
SOBI, INC
$51
Myovant Sciences Inc.
$51
Acrotech Biopharma Inc.
$45
Mirati Therapeutics, Inc.
$44
Pharmacosmos Therapeutics Inc.
$43
Array BioPharma Inc.
$42
Myriad Genetic Laboratories, Inc.
$39
Mylan Institutional Inc.
$38
Acrotech Biopharma LLC
$37
APO-PHARMA USA, INC.
$36
Aveo Pharmaceuticals, Inc.
$36
SUN PHARMACEUTICAL INDUSTRIES INC.
$34
EISAI INC.
$32
PharmaEssentia USA Corporation
$31
Global Blood Therapeutics, Inc.
$30
Aurobindo Pharma USA, Inc.
$30
Janssen Pharmaceuticals, Inc
$30
Catalyst Pharmaceuticals, Inc.
$29
JAZZ PHARMACEUTICALS INC.
$28
Secura Bio, Inc.
$28
Heron Therapeutics, Inc.
$26
Sobi, Inc
$25
AMAG Pharmaceuticals, Inc.
$24
MorphoSys, US Inc.
$23
Genmab U.S., Inc.
$21
Seattle Genetics, Inc.
$20
Deciphera Pharmaceuticals Inc.
$20
Clovis Oncology, Inc.
$20
Kyowa Kirin, Inc.
$18
Verity Pharmaceuticals Inc.
$18
Agios Pharmaceuticals, Inc.
$16
Novocure Inc.
$14
Spectrum Pharmaceuticals Inc.
$14
Immunomedics, Inc.
$12
Chiesi USA, Inc.
$12
Top 3 companies account for 21.3% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · ALIMTA · ALTUVIIIO · ALUNBRIG · AYVAKIT · Abraxane · Afstyla · Alecensa · BAVENCIO · BELEODAQ · BENDEKA · BESREMI · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Bavencio · Beleodaq · Blincyto · Braftovi · CABLIVI · CABOMETYX · CALQUENCE · CHANTIX · CINVANTI · COPIKTRA · CYRAMZA · Cabometyx · DARZALEX · DEFERIPRONE · DOPTELET · Doptelet · ELIQUIS · ELITEK · EMPLICITI · ENHERTU · ENJAYMO · EPKINLY · ERLEADA · Epkinly · FARESTON · FERAHEME · FERRIPROX · FIRDAPSE · FOTIVDA · FOUNDATIONONE · FRUZAQLA · Farydak · Folotyn · Fulphila · GAZYVA · GILOTRIF · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · Idelvion · Imbruvica · JAKAFI · JEVTANA · KANJINTI · KEYTRUDA · KIMMTRAK · KISQALI · KRAZATI · Kyprolis · LENVIMA · LIBTAYO · LONSURF · LORBRENA · LUMAKRAS · LUPRON DEPOT · LUTATHERA · LYNPARZA · Lenvima · MEKINIST · MONJUVI · MONOFERRIC · MVASI · MYLOTARG · MYRISK · NERLYNX · NINLARO · Nerlynx · Neulasta · Nplate · Nubeqa · OCTAGAM IMMUNE GLOBULIN (HUMAN) · OGSIVEO · OJJAARA · ONUREG · OPDIVO · ORGOVYX · OXBRYTA · Optune · PADCEV · PANZYGA · PEMAZYRE · PIQRAY · PLUVICTO · PROMACTA · PROVENGE · Padcev · Perjeta · Polivy · Pomalyst · QINLOCK · QUZYTTIR · REBIF · REBLOZYL · ROLVEDON · RYBREVANT · Revlimid · Rezlidhia · Rubraca · SARCLISA · SCEMBLIX · SHINGRIX · SOMATULINE DEPOT · SPRYCEL · SUTENT · SYNDROS · Somatuline Depot · Stivarga · Sylvant · TABRECTA · TAGRISSO · TASIGNA · TAZVERIK · TECENTRIQ · TECVAYLI · TEPMETKO · TIBSOVO · TUKYSA · Tavalisse · Tecentriq · Trelstar · Trodelvy · ULTOMIRIS · Ultomiris · VENCLEXTA · VERZENIO · VOTRIENT · VPRIV · XALKORI · XARELTO · XPOVIO · XTANDI · XYNTHA · Xermelo · Xospata · Xtandi · YONSA · ZEJULA · ZEPZELCA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (97%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians. Total industry engagement is in the top 9% for optician in CA.
Geographic Context
Opticians within 10 mi
612
Per 100K population
25.0
County median income
$89,672
Nearest hospital
KAISER FOUNDATION HOSPITAL, RIVERSIDE
3.7 mi
3.7 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Reyes is a mixed practice specialist, with above-average Medicare volume (top 3% in CA), with low-engagement industry engagement in the top 9% of CA peers, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Reyes experienced with iron infusion (injectafer)?
Based on Medicare claims data, Dr. Reyes performed 19,500 iron infusion (injectafer) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Reyes receive payments from pharmaceutical companies?
Yes. Dr. Reyes received a total of $19,713 from 91 companies across 1,070 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Reyes's costs compare to other opticians in Corona?
Dr. Reyes's average Medicare payment per service is $3. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Reyes) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Opticians in Corona
Browse opticians in Corona ranked by procedure volume and transparency data.
Highest volume
Top Opticians in CA
Opticians ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Opticians in CA
Which CA opticians receive the most from drug and device companies.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
Merck Sharp & Dohme Corporation Payments to Doctors
See all physicians who received payments from Merck Sharp & Dohme Corporation.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology